Iopidine®
Apraclonidine 0.5%, 1% · ophthalmic solution
Antiglaucoma
Approved uses
Post-surgical elevations in IOP after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy
1% solution: one drop in the operative eye one hour before the laser, and a second drop immediately after it is finished
The 1% strength exists only for this peri-laser use, given twice around the procedure rather than on a schedule
Short-term adjunctive pressure reduction in patients already on maximally tolerated therapy
0.5% solution: one to two drops in the affected eye(s) three times daily
Short-term by design: tachyphylaxis and allergic conjunctivitis limit how long it keeps working
OFF-LABELNot in the FDA label for this product
Horner syndrome, confirming an oculosympathetic palsy
One drop of the 0.5% solution in each eye, read at 45 to 60 minutes
n=85 eyes · reversal in all
This is the test that displaced cocaine. Denervation makes the dilator's alpha-1 receptors supersensitive, so apraclonidine dilates the affected pupil while very weakly constricting the normal one, and the anisocoria REVERSES. Across 31 eyes with oculosympathetic paresis and 54 control eyes, all confirmed against the cocaine test, apraclonidine dilated the affected pupils by a mean 2.04 mm and constricted the controls by 0.14 mm, reversed the anisocoria in every Horner case, and lifted the ptotic lid by a mean 1.75 mm. The authors concluded it has at least the sensitivity and specificity of the cocaine test. Two cautions the study does not cover: supersensitivity takes days to weeks to develop, so an acute Horner can test falsely negative, and apraclonidine is avoided in infants for the risk of central nervous system depression.
Contraindications
- Receiving monoamine oxidase inhibitor therapy
- Hypersensitivity to apraclonidine, any other component of this medication, or clonidine
0.5% (5 mg/mL apraclonidine as base), 5 mL and 10 mL dropper bottles; 1% (10 mg/mL apraclonidine as base), 0.1 mL single-dose dispensers
Apraclonidine is a relatively selective alpha adrenergic agonist (alpha-2 selective, per the 0.5% label) that reduces intraocular pressure (IOP) when instilled in the eye. Onset is usually within one hour, and maximum IOP reduction occurs about three hours after instillation (0.5%) or usually three to five hours after a single dose (1%). Dose-response studies of 0.125% to 1.0% place 0.5% at the top of the IOP reduction curve (0.5% label). The 0.5% label states that aqueous fluorophotometry studies demonstrate its predominant mechanism is reduction of aqueous flow via stimulation of the alpha-adrenergic system; the 1% label states the precise mechanism is not completely established and that its predominant action may be related to a reduction of aqueous formation.
Warnings & Precautions
- Cardiovascular collapse and systemic adverse reactions: Topical apraclonidine has been reported to cause cardiovascular collapse requiring intubation and ventilation in pediatric patients 6 years and younger, including neonates. Systemic adverse reactions such as prolonged lethargy and unresponsiveness, apnea, hypoxia, respiratory failure, bradycardia, hypertension, hypotension, hypothermia, hypotonia and pallor have also been reported; appropriate monitoring in a clinical setting should be in place (1% label).
- Systemic toxicity if swallowed: Both labels restrict use to the eye and state the solution is not for injection or oral ingestion. In both labels, ingestion of the 0.5% solution has been reported to cause bradycardia, drowsiness and hypothermia.
- Exaggerated IOP reduction: Apraclonidine is a potent depressor of IOP, and patients who develop exaggerated reductions in IOP should be closely monitored (1% label).
- Loss of IOP control: The IOP lowering effect of 0.5% diminishes over time in some patients (tachyphylaxis), which appears to be an individual occurrence with a variable time of onset and should be closely monitored. Patients on maximally tolerated medical therapy who are treated with 0.5% to delay surgery should have frequent follow-up examinations and periodic visual field monitoring, and treatment should be discontinued if the intraocular pressure rises significantly (0.5% label).
- Allergic-like reaction: The 0.5% solution can cause an allergic-like reaction characterized wholly or in part by hyperemia, pruritus, discomfort, tearing, foreign body sensation, and edema of the lids and conjunctiva; if ocular allergic-like symptoms occur, therapy should be discontinued (0.5% label).
- Cardiovascular effects in at-risk patients: Apraclonidine had minimal effect on heart rate or blood pressure in clinical studies, but its preclinical pharmacologic profile suggests caution in severe cardiovascular disease, including hypertension (severe, uncontrolled disease in the 0.5% label). Also use with caution in coronary insufficiency (severe, in the 1% label), recent myocardial infarction, cerebrovascular disease, chronic renal failure, Raynaud's disease or thromboangiitis obliterans.
- Vasovagal attack: The possibility of a vasovagal attack should be considered, and caution used in patients with a history of such episodes; the 1% label places this risk during laser surgery.
- Cardiovascular effects in renal or hepatic impairment: Topical apraclonidine has not been studied in renal failure, but structurally related clonidine undergoes a significant increase in half-life in severe renal impairment, so close monitoring of cardiovascular parameters is advised in patients with impaired renal function. Close monitoring is also advised in impaired liver function, because systemic clonidine is partly metabolized in the liver (0.5% label).
- Unstudied drug interactions: Interactions with other agents have not been investigated for the 1% solution (1% label).
- Additive CNS effects: Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered (0.5% label).
- Additive cardiovascular effects: Since apraclonidine may reduce pulse and blood pressure, caution is advised with drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and cardiac glycosides, and patients using cardiovascular drugs concurrently should have pulse and blood pressure frequently monitored. Caution should also be exercised with simultaneous use of clonidine and other similar pharmacologic agents (0.5% label).
- Additive hypotension with neuroleptics: An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy (0.5% label).
- Masked hypoglycemia: Systemic clonidine may inhibit the production of catecholamines in response to insulin-induced hypoglycemia and mask the signs and symptoms of hypoglycemia (0.5% label).
- Altered response with tricyclic antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine, and it is not known whether they reduce the IOP lowering effect of apraclonidine. Caution is advised in patients taking them, because they can affect the metabolism and uptake of circulating amines (0.5% label).
- Depression: Caution and monitoring of depressed patients are advised, since apraclonidine has been infrequently associated with depression (0.5% label).
- Decreased mental alertness: Apraclonidine can cause dizziness and somnolence. Patients who engage in hazardous activities requiring mental alertness should be warned of the potential for a decrease in mental alertness while using it (0.5%) or on the day of surgery (1%).
- Preservative absorbed by soft contact lenses: The benzalkonium chloride preservative may be absorbed by soft contact lenses, so lenses should be removed during instillation and may be reinserted 15 minutes after (0.5% label).
- Contamination of the solution: Do not touch the dropper tip to any surface, as this may contaminate the contents (0.5% label).
Common Side Effects
0.5%: the most common ocular reactions were discomfort, hyperemia and pruritus (5 to 15% of patients), and dry mouth occurred in approximately 10%; blanching, blurred vision, conjunctivitis, discharge, dry eye, foreign body sensation, lid edema and tearing were reported in 1 to 5%, and the overall discontinuation rate in clinical studies was 15%. 1%: ocular injection, upper lid elevation, irregular heart rate, nasal decongestion, ocular inflammation, conjunctival blanching and mydriasis occurred in less than 2% of patients in laser surgery. Postmarketing reports include bradycardia and hypersensitivity (0.5%), and with 1%, hypersensitivity and cardiovascular collapse requiring intubation and ventilation in pediatric patients 6 years and younger, including neonates.
Pregnancy: Apraclonidine HCl was embryocidal in rabbits at an oral dose of 3 mg/kg, and dose related maternal toxicity was observed in pregnant rats at 0.3 mg/kg; the labels put these at 60 and 6 times (0.5%) or 150 and 15 times (1%) the maximum recommended human dose. There are no adequate and well controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether apraclonidine is excreted in human milk. With 0.5%, caution should be exercised when it is given to a nursing woman; with 1%, a decision should be made to discontinue nursing temporarily for the one day on which it is used.
Safety and effectiveness in pediatric patients have not been established (both labels). The 1% label adds that, during postmarketing surveillance, cardiovascular collapse requiring intubation and ventilation, prolonged lethargy and unresponsiveness, apnea, hypoxia, respiratory failure, bradycardia, hypertension, hypotension, hypothermia, hypotonia, and pallor have been reported in pediatric patients 6 years and younger, including neonates, following topical administration of apraclonidine.